Building 10, CRC, 1 East, Room 1-3140, 10 Center Drive, MSC 1109, Bethesda, Maryland 20892-1109, USA.
J Clin Endocrinol Metab. 2010 Mar;95(3):1207-19. doi: 10.1210/jc.2009-2282. Epub 2010 Jan 20.
Because ectopic ACTH-secreting (EAS) tumors are often occult, improved imaging is needed.
Our objective was to evaluate the utility of [(111)In-DTPA-d-Phe]pentetreotide scintigraphy [octreotide (OCT)] imaging at 6 mCi [low OCT (LOCT)] and 18 mCi [high OCT (HOCT)], [(18)F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) and [(18)F]l-3,4-dihydroxyphenylalanine (F-DOPA)-PET scans, computed tomography (CT), and magnetic resonance imaging (MRI).
The study was a prospective evaluation at a clinical research center.
Forty-one subjects participated, 30 (17 female) with resected EAS tumors and 11 (three female) with occult EAS, based on inferior petrosal sinus sampling results and imaging studies.
INTERVENTION included CT and MRI of neck, chest, abdomen, LOCT (with or without HOCT) and FDG- or F-DOPA-PET without CT every 6-12 months.
Tumor identification was the main outcome measure.
Most recent results were analyzed. Eighteen patients had tumor resected on the first visit; otherwise, surgery occurred 33 +/- 25 (9-99) months later. Tumor size was 1.9 +/- 1.7 (0.8-8.0) cm; 83% were intrathoracic. CT, MRI, LOCT, HOCT, FDG-PET, and F-DOPA-PET had sensitivities per patient of 93% [95% confidence interval (CI) = 79-98%], 90% (95% CI = 74-96%), 57% (95% CI = 39-73%), 50% (95% CI = 25-75%), 64% (95% CI = 35-85%), and 55% (95% CI = 28-79%) and positive predictive values (PPV) per lesion of 66, 74, 79, 89, 53, and 100%, respectively. LOCT and PET detected only lesions seen by CT/MRI; abnormal LOCT or F-DOPA-PET improved PPV of CT/MRI. By modality, the fraction of patients with one or more false-positive findings was 50% by CT, 31% by MRI, 18% by L/HOCT, and 18% by FDG-PET. Eight occult EAS patients had 64 +/- 58 (9-198) months follow-up; others had none.
High sensitivity and PPV suggest thoracic CT/MRI plus LOCT scans for initial imaging, with lesion confirmation by two modalities.
由于异位 ACTH 分泌(EAS)肿瘤常常是隐匿性的,因此需要改进的影像学检查。
我们的目的是评估[111In-DTPA-d-Phe]pentetreotide 闪烁扫描(奥曲肽(OCT))在 6mCi[低 OCT(LOCT)]和 18mCi[高 OCT(HOCT)]、[18F]氟脱氧葡萄糖(FDG)-正电子发射断层扫描(PET)和[18F]l-3、4-二羟基苯丙氨酸(F-DOPA)-PET 扫描、计算机断层扫描(CT)和磁共振成像(MRI)中的应用。
这是一项在临床研究中心进行的前瞻性评估。
41 名患者参与了研究,其中 30 名(17 名女性)患者有已切除的 EAS 肿瘤,11 名(3 名女性)患者有隐匿性 EAS,基于蝶鞍旁窦采样结果和影像学研究。
干预措施包括颈部、胸部、腹部的 CT 和 MRI、LOCT(有或无 HOCT)和 FDG 或 F-DOPA-PET,每 6-12 个月进行一次 CT。
肿瘤识别是主要观察指标。
分析了最近的结果。18 名患者在首次就诊时即进行了肿瘤切除;否则,在 33 +/- 25(9-99)个月后进行手术。肿瘤大小为 1.9 +/- 1.7(0.8-8.0)cm;83%为胸部。CT、MRI、LOCT、HOCT、FDG-PET 和 F-DOPA-PET 的每位患者的敏感性分别为 93%(95%置信区间(CI)=79-98%)、90%(95%CI=74-96%)、57%(95%CI=39-73%)、50%(95%CI=25-75%)、64%(95%CI=35-85%)和 55%(95%CI=28-79%),每个病变的阳性预测值(PPV)分别为 66、74、79、89、53 和 100%。LOCT 和 PET 仅检测到 CT/MRI 可见的病变;异常 LOCT 或 F-DOPA-PET 提高了 CT/MRI 的 PPV。按检查方式分析,有 50%的 CT、31%的 MRI、18%的 LO/HOCT 和 18%的 FDG-PET 有一个或多个假阳性发现。8 名隐匿性 EAS 患者随访 64 +/- 58(9-198)个月,其余患者无随访。
高敏感性和 PPV 提示进行胸部 CT/MRI 加 LOCT 扫描作为初始影像学检查,并通过两种方式确认病变。